help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2007-1559
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mauras, N.
Right arrow Articles by Bishop, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mauras, N.
Right arrow Articles by Bishop, K.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Pediatric Endocrinology
Right arrow Male Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 3 823-831
Copyright © 2008 by The Endocrine Society

Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years

Nelly Mauras, Lilliam Gonzalez de Pijem, Helen Y. Hsiang, Paul Desrosiers, Robert Rapaport, I. David Schwartz, Karen Oerter Klein, Ravinder J. Singh, Anna Miyamoto and Kim Bishop

Divisions of Endocrinology at Nemours Children’s Clinic-Jacksonville (N.M., K.B.), Jacksonville, Florida 32207; Nemours Children’s Clinic-Pensacola (H.Y.H.), Pensacola, Florida 32504; Nemours Children’s Clinic-Orlando (P.D.), Orlando, Florida 32806; University of Puerto Rico Medical Center (L.G.d.P.), Rio Piedras, Puerto Rico 00936; Mount Sinai Medical Center (R.R.), New York, New York 10029; University of South Carolina (I.D.S.), Columbia, South Carolina 29203; University of California, San Diego (K.O.K.), San Diego, California 92121; Department of Biostatistics (A.M.), AstraZeneca, Wilmington, Delaware 19850; and Department of Laboratory Medicine and Pathology (R.J.S.), Mayo Clinic, Rochester, Minnesota 55902

Address all correspondence and requests for reprints to: Nelly Mauras, Dr. Nemours Children’s Clinic, Division of Endocrinology, 807 Children’s Way, Jacksonville, Florida 32207. E-mail: nmauras{at}nemours.org.

Context: The process of epiphyseal fusion during puberty is regulated by estrogen, even in males.

Objective: Our objective was to investigate whether anastrozole, a potent aromatase inhibitor, could delay bone age acceleration and increase predicted adult height in adolescent boys with GH deficiency.

Methods: Fifty-two adolescent males with GH deficiency treated with GH were randomized to cotreatment with anastrozole or placebo daily for up to 36 months.

Results: Fifty subjects completed 12 months, 41 completed 24 months, and 28 completed 36 months. Linear growth was comparable between groups; however, there was a significantly slower increase in bone age advancement from baseline in the anastrozole group vs. placebo group after 2 yr (+1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P < 0.0001) and after 3 yr (+2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P < 0.0001). This resulted in a net increase in predicted adult height of +4.5 ± 1.2 cm in the anastrozole group at 24 months and +6.7 ± 1.4 cm at 36 months as compared with a 1-cm gain at both time points in the placebo group. Estradiol and estrone concentrations increased less in the anastrozole group compared with placebo group. All boys on the aromatase inhibitor had normal tempo of virilization. Safety data, including glucose, and plasma lipid concentrations were comparable between groups.

Conclusions: Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2–3 yr. This treatment offers an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up is needed to elucidate fully the safety and efficacy of this approach.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
N. Mauras, K. Bishop, D. Merinbaum, U. Emeribe, F. Agbo, and E. Lowe
Pharmacokinetics and Pharmacodynamics of Anastrozole in Pubertal Boys with Recent-Onset Gynecomastia
J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2975 - 2978.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. J. Santen, H. Brodie, E. R. Simpson, P. K. Siiteri, and A. Brodie
History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target
Endocr. Rev., June 1, 2009; 30(4): 343 - 375.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Cohen, A. D. Rogol, C. L. Deal, P. Saenger, E. O. Reiter, J. L. Ross, S. D. Chernausek, M. O. Savage, J. M. Wit, and on behalf of the 2007 ISS Consensus Workshop parti
Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop
J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4210 - 4217.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society